Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 3, 2026, Prime Medicine, Inc. (PRME) has a Wall Street consensus price target of $17.25, based on estimates from 9 covering analysts. With the stock currently trading at $4.62, this represents a potential upside of +273.4%. The company has a market capitalization of $833M.
Analyst price targets range from a low of $12.00 to a high of $23.00, representing a 64% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PRME trades at a trailing P/E of -2.8x. Analysts expect EPS to grow +24.6% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PRME stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for PRME is $17.25, representing 273.4% upside from the current price of $4.62. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRME has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $17.25 implies 273.4% upside from current levels.
PRME's current price is $4.62 with a consensus target of $17.25 (273.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $23 for PRME, while the most conservative target is $12. The consensus of $17.25 represents the median expectation. These targets typically reflect 12-month expectations.
PRME is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRME stock forecast based on 9 Wall Street analysts shows a consensus price target of $17.25, with estimates ranging from $12 (bear case) to $23 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRME, with a "Buy" consensus rating and $17.25 price target (273.4% upside). 5 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRME analyst price targets range from $12 to $23, a 64% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17.25 consensus represents the middle ground.